COLL
Collegium Pharmaceutical, Inc.
COLL trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over COLL overall, supported by stronger fundamentals and stronger modeled upside.
COLL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
COLL's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
COLL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.5x | $24.95 | — |
| Cheap | 13x | $12.57 | -50% |
| Fair | 19x | $19.08 | -24% |
| Current | 25x | $24.95 | — |
| Expensive | 34x | $33.57 | +35% |
Historical ranges are pointers, not guarantees.
COLL's PE is in its expensive range at 25x. On analysts' estimates for next year's earnings, today's price would be 3.5x, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over COLL in the historical PE scenario, which offers more potential upside but is not a forecast.
COLL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect COLL's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over COLL on the outlook, with more favorable earnings and profitability expectations.
COLL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.07 | +607% |
| Q3 2026 | $1.00 | -38% |
| Q2 2026 | $1.24 | +19% |
| Q1 2026 | $2.04 | +67% |
| Q4 2025 | $1.71 | -8.1% |
| Q3 2025 | $1.61 | -31% |
| Q2 2025 | $1.04 | -60% |
| Q1 2025 | $1.22 | -49% |
| Q4 2024 | $1.86 | +58% |
COLL's earnings per share have fallen from their peak: $1.00 over the past year, against $2.72 in mid-2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over COLL on earnings, with more consistent year-over-year improvement.
COLL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $216.3M | +3.3% |
| Q2 2026 | $199.9M | +6.3% |
| Q1 2026 | $193.5M | +8.9% |
| Q4 2025 | $205.4M | +13% |
| Q3 2025 | $209.4M | +31% |
| Q2 2025 | $188M | +29% |
| Q1 2025 | $177.8M | +23% |
| Q4 2024 | $181.9M | +22% |
COLL's revenue has grown year over year for 18 quarters in a row: $216M last quarter, up 3.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -16 points |
| Q2 2026 | 1.9% | -17 points |
| Q1 2026 | 16% | +3.8 points |
| Q4 2025 | 30% | +8.6 points |
| Q3 2025 | 30% | +7.8 points |
| Q2 2025 | 19% | -14 points |
| Q1 2025 | 12% | -22 points |
| Q4 2024 | 21% | -20 points |
COLL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over COLL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
COLL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $86.3M | +10% |
| Q2 2026 | $70.8M | -2.1% |
| Q1 2026 | $56.8M | +4.1% |
| Q4 2025 | $122.4M | +46% |
| Q3 2025 | $78.3M | +$87.5M |
| Q2 2025 | $72.4M | +7.8% |
| Q1 2025 | $54.6M | -11% |
| Q4 2024 | $84.1M | +15% |
COLL generated $336M in free cash flow over the past year, up 16% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
COLL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +20% | +6.7M shares |
| 1 year | -0.8% | -329K shares |
| 3 years | -7% | -2.9M shares |
| 5 years | +7.9% | +2.8M shares |
| Available history | +16% | +5.5M shares |
COLL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | $25M |
| Q3 2024 | — |
| Q4 2023 | $25M |
| Q4 2022 | $7.6M |
| Q4 2021 | $32.3M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
COLL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.6x | Very low |
COLL's net debt is less than a year of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over COLL on leverage, with a lower net debt burden relative to earnings.
COLL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 25.6 | Neutral |
COLL's weekly RSI is 39 (neutral) and its Stochastic is 26 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
COLL PE vs Healthcare Sector
| Metric | COLL | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 3.5% below |
| PE % | 66 | 29 | 37 pts above |
COLL is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over COLL on valuation relative to its sector.
COLL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.2 | 7.5% above |
| 20 week MA | $27.2 | 8.2% below |
| 50 week MA | $34.7 | 28% below |
| 100 week MA | $33.7 | 26% below |
| 200 week MA | $31.6 | 21% below |
COLL has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 21% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over COLL on trend strength, trading above more of its moving averages.
COLL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.0 | $18.6 | -12% |
| 2021 | $18.6 | $19.5 | +4.9% |
| 2022 | $19.5 | $23.0 | +18% |
| 2023 | $23.0 | $30.8 | +34% |
| 2024 | $30.8 | $29.1 | -5.4% |
| 2025 | $29.1 | $49.8 | +71% |
| 2026 YTD | $49.8 | $25.0 | -50% |
COLL is down 50% so far in 2026, after finishing higher in four of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over COLL on returns for 2026, with the stronger performance.